---
figid: PMC7961479__cancers-13-01115-g002
figtitle: Activating mutations and activation of alternative upstream receptors confer
  resistance to inhibitors targeting aberrant MAPK signaling
organisms:
- Homo sapiens
- Mus musculus
- Canis lupus familiaris
- Lareunionomyces loeiensis
pmcid: PMC7961479
filename: cancers-13-01115-g002.jpg
figlink: pmc/articles/PMC7961479/figure/cancers-13-01115-f002/
number: F2
caption: Activating mutations and activation of alternative upstream receptors confer
  resistance to inhibitors targeting aberrant MAPK signaling. Mutations in RAS, RAF,
  and MEK, as well as RAF amplification and activation of RAS-independent RAF variants,
  have been implicated in bypassing MAPK inhibition. Upregulation and activation of
  additional receptor tyrosine kinases may also contribute to enhanced MAPK signaling
  or alternative pathway activation, such as PI3K/Akt [,,,,]. EMT has also been shown
  to contribute to BRAF inhibitor resistance.
papertitle: Resistance to Molecularly Targeted Therapies in Melanoma.
reftext: Meet Patel, et al. Cancers (Basel). 2021 Mar;13(5):1115.
year: '2021'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9502116
figid_alias: PMC7961479__F2
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
- Canis lupus familiaris
redirect_from: /figures/PMC7961479__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7961479__cancers-13-01115-g002.html
  '@type': Dataset
  description: Activating mutations and activation of alternative upstream receptors
    confer resistance to inhibitors targeting aberrant MAPK signaling. Mutations in
    RAS, RAF, and MEK, as well as RAF amplification and activation of RAS-independent
    RAF variants, have been implicated in bypassing MAPK inhibition. Upregulation
    and activation of additional receptor tyrosine kinases may also contribute to
    enhanced MAPK signaling or alternative pathway activation, such as PI3K/Akt [,,,,].
    EMT has also been shown to contribute to BRAF inhibitor resistance.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Braf
  - Braf-rs1
  - Rac1
  - Akt1
  - Tsc2
  - Slc12a3
  - Tsc22d1
  - Mdk
  - Rheb
  - Ephb2
  - Mapk1
  - Mtor
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - BRAF
  - RAC1
  - RNASE1
  - AKT1
  - AKT2
  - AKT3
  - TSC2
  - SLC12A3
  - TSC1
  - TESC
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - RHEB
  - RHEBP1
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - LOC475395
  - 'N'
  - MEKO
---
